SCHEMBL13846397

SCHEMBL13846397

C/C(=C/C(=O)c1ccccc1)Nc1ccccc1Oc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ RAB9A P51151 5/20 0.60
▸ MAPK1 P28482 5/20 0.60
▸ NPC1 O15118 4/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ GAA P10253 4/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ THRB P10828 1/20 0.52
▸ ADRA2C P18825 1/20 0.52
▸ L3MBTL1 Q9Y468 4/20 0.52
▸ POLB P06746 2/20 0.52
▸ LMNA P02545 2/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ TSHR P16473 3/20 0.51
▸ ATM Q13315 2/20 0.51
▸ PKM P14618 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13846410 0.92 RAB9A (0.68) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13849752 0.92 MAPT (0.61) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL15504786 0.92 MAPT (0.58) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13849747 0.91 MAPT (0.57) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846403 0.91 MAPT (0.58) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846402 0.89 MAPT (0.55) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846404 0.87 MAPT (0.59) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846411 0.86 MAPT (0.74) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846398 0.84 MAPT (0.52) MAPTRAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL13846399 0.83 MAPT (0.51) MAPTRAB9AMAPK1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2014-03-13 — — US disclosed
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2014-03-13 — — US disclosed
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2009-05-28 — — US disclosed
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2009-05-28 — — US disclosed
EP-2039677-A1 ORGANIC COMPOUNDS CONTAINING HETEROATOMS AND THEIR USE IN ZIEGLER-NATTA CATALYST WITH SINGLE ACTIVATION CENTER SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2009-03-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073500-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST CCNT1, SP1, CCNT2 MAPT 450/4885RAB9A 4804/4885MAPK1 2104/4885
US-20090137383-A1 CLASS OF ORGANIC COMPOUNDS CONTAINING HETEROATOM AND ITS APPLICATIONS IN PREPARING SINGLE-SITE ZIEGLER-NATTA CATALYST CCNT1, SP1, CCNT2 MAPT 450/4885RAB9A 4804/4885MAPK1 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback